Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions

23 April 2022 : Clinical Research

Liying Han^1CEF, Guanyong He^1CDE, Yingjie Mei^2CD, Qing Yu^3BF, Minning Zhao^3BF, Fu Luo^4B, Guanxun Cheng^1AEG*, Wen Liang^3AE

DOI: 10.12659/MSM.935307

Med Sci Monit 2022; 28:e935307

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Patients’ characteristics.

Variable	Value
	Median (interquartile range)
Age (years)	70 (65–76)
tPSA(ng/ml)	14.30 (7.33–35.11)
f/t PSA	0.12 (0.08–0.16)
PSAD (ng/ml/cm)	0.20 (0.11–0.52)

Benign	52 (62%)
PCa	32 (38%)
GS6	7 (21.9%)
GS7	6 (18.8%)
GS8	8 (25%)
GS9	9 (25.1%)
GS10	2 (6.2%)
tPSA – total prostate-specific antigen; f/t PSA – free/total prostate-specific antigen; PSAD – prostate-specific antigen density; PCa – prostate cancer; GS – Gleason score.

Back to the Article